

13 Feb 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: *Scrip* asks what 2022 holds for deal-making; Pfizer looks for transactions to add to its top line; Sanofi unworried about JAK threat to Dupixent; what information do healthcare professionals want from pharma; and Amgen looks to its established brands for growth.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 11 February 2022, including: *Scrip* asks what 2022 holds for deal-making; [Pfizer Inc.](#) looks for transactions to add to its top line; [Sanofi](#) unworried about JAK threat to Dupixent; what information do healthcare professionals want from pharma; and [Amgen, Inc.](#) looks to its established brands for growth.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Scrip Asks...What Does 2022 Hold For Biopharma? Part 2: Deal Making, M&A And Financial Markets](#)" - Scrip, 8 Feb, 2022.)

(Also see "[Pfizer Shopping For Deals That Will Add \\$25bn To 2030 Revenues](#)" - Scrip, 9 Feb, 2022.)

(Also see "[Sanofi Unruffled By JAK Threat To Dupixent](#)" - Scrip, 4 Feb, 2022.)

(Also see "[What Physicians Want: Less of Promotional Content](#)" - Scrip, 7 Feb, 2022.)

(Also see "[*Amgen's Growth Story Relies Mainly On Continuing Plot Lines*](#)" - Scrip, 8 Feb, 2022.)

[*Click here to explore this interactive content online*](#) ✎